Early Phase Clinical Research Support

早期临床研究支持(EPCRS)的目的是提供资金，支持短期、 来自梅奥临床癌症中心(MCCC)科学研究的试点和I期临床研究 调查人员。这一资源的主要功能是鼓励开发新的预防措施， 诊断、检测和治疗策略。因此，对有希望的想法的支持可以导致 将继续支持更多的最终试验和资助赠款。 Steven Alberts博士提供EPCRS的总体指导和监督；Jann Sarkaria博士是 早期临床研究委员会。所有申请环境影响评估资助的建议研究均包括 评估以确保符合CCSG指南定义的资格标准。除了个人科学研究 优点，建议的研究评估了未来与现有和发展中的MCCC的潜在交叉点 方案，以及外部资金的潜力。 EPCRS支持包括研究协调和研究新药(IND)管理。学习 协调包括参与者试验管理支持，以识别、招募和输入参与者 研究以及数据编辑和跟踪。IND应用程序支持包括监管协助和 管理所有IND申请和EPCRS批准研究的进度报告。

The purpose of Early Phase Clinical Research Support (EPCRS) is to provide funding to support short-term, pilot, and phase I clinical research studies which originate from Mayo Clinic Cancer Center (MCCC) scientific investigators. The primary function of this resource is to encourage the development of novel prevention, diagnostic, detection, and treatment strategies. Therefore, support of promising ideas which can lead to more definitive trials and funded grants will continue to be supported. Dr. Steven Alberts provides overall direction and oversight of the EPCRS; Dr. Jann Sarkaria is the chair of the Early Phase Clinical Research Committee. All proposed studies requesting EPCRS support are assessed to ensure eligibility criteria as defined by the CCSG guidelines. In addition to individual scientific merit, proposed studies are assessed for potential future intersections with existing and developing MCCC programs, as well as potential for extramural funding. EPCRS support includes study coordination and Investigational New Drug (IND) management. Study coordination includes participant trial management support to identify, recruit, and enter participants onto study as well as data editing and tracking. IND application support includes regulatory assistance and management for all IND applications and progress reports for EPCRS approved studies.